symptomatic intracranial hemorrhage, or ambulate independently at discharge. They were more likely to die or be discharged to hospice.

Conclusions Though use of EVT in GWTG-Stroke for in-hospital stroke remains low, it more than doubled in the past decade. Compared with community onset stroke, these patients have longer intervals to CT and arterial puncture, with associated worse functional outcomes. While there may be important differences in baseline patient characteristics between the groups, efforts must still be made to shorten time to reperfusion for in-hospital strokes.

Disclosures F. Akbik: None. H. Xu: None. Y. Xian: None. S. Shah: None. E. Smith: None. D. Bhatt: None. R. Matsouaka: None. G. Fonarow: None. L. Schwamm: None.

E-056 THE 'CLOT' SUMMIT – FIRST 5 YEARS OF A FOCUSED INCUBATOR PLATFORM FOR GUIDING STROKE RESEARCH

¹A Rai*, ²J Fiehler, ³R McCarthy, ⁴A Siddiqui, ⁵D Liebeskind, ⁶W Hacke. ¹INTERVENTIONAL NEURORADIOLOGY, WEST VIRGINIA UNIVERSITY, Morgantown, WV; ²NEURORADIOLOGY, University Medical Center Hamburg-Eppendorf, Hamburg, GERMANY; ³Scientific Affairs, Cerenovus, Miami, FL; ⁴Neurosurgery, University of Buffalo, Buffalo, NY; ⁵Neurology, University of California, Los Angeles, Los Angeles, CA; ⁶Neurology, University of Heidelberg, Heidelberg, GERMANY

10.1136/neurintsurg-2020-SNIS.92

Background Advances in stroke care like most innovations in medicine have happened gradually, over time, in increments and have typically benefitted from the collaborative efforts of a diverse group with a common goal. The CLOT summit inaugurated in 2015 created an ecosystem guided by these principles to evaluate and develop pathways for enhancing stroke care.

Methodology Three core groups are invited to participate. These include scientists involved in clot research, engineers involved in device development and physicians involved in interventional and medical treatment of acute ischemic stroke. The initial format followed a focused group discussion and presentation on key topics leading to development of targeted projects. In subsequent years the outcome from previous year's summit was evaluated and a future course in basic and clinical research charted. A key clinical component was improving procedural performance and defining unmet needs.

Results To date, the output has covered several areas. Basic clot research: ex vivo clot analysis resulted in five registries in the US (one) and the EU (four) with the aim of multicenter collection of thrombectomy specimen with centralized analysis. This has yielded several publications in the JNIS and elsewhere. Procedure optimization: Pre-intervention imaging analysis involved multiple contributions on thrombus imaging using CT/CTA/MR. In-Vitro modeling for thrombectomy procedures centered around procedural aspects (tortuosity, the effects of flow and pressure, embolization to new territory) and clot interaction (fibrinous or calcified clots versus friable clots). Progress in device iteration was part of procedure optimization based on in-vitro modeling and review of challenging cases highlighting a potential unmet solution. Clinical Studies: These were a product of the first two and involve clinical studies related to new devices and clinical registry for calcified clots.

Conclusion The CLOT summit represents a novel incubator platform bringing together expertise in a coordinated fashion that has resulted in meaningful basic and clinical contribution to the evolving stroke care. Key outcomes of the summit over the first 5-years are presented.

Disclosures A. Rai: 2; C; Cerenovus, Microvention, Stryker Neurovascular. J. Fiehler: 2; C; Cerenovus. R. McCarthy: None. A. Siddiqui: 2; C; Cerenovus. D. Liebeskind: 2; C; Cerenovus. W. Hacke: 2; C; Cerenovus.

E-057 CLOT PERVIOUSNESS BUT NOT DENSITY IS ASSOCIATED WITH FIRST-PASS RECANALIZATION OF ASPIRATION THROMBECTOMY IN THE COMPASS TRIAL

¹M Mokin*, ²M Waqas, ³J Fifi, ³R De Leacy, ⁴D Fiorella, ²E Gu, ²E Levy, ²K Snyder, ⁵R Hanel, ⁵A Aghaebrahim, ⁶K Woodward, ⁶H Hixson, ⁷M Chaudry, ⁸A Spiotta, ⁹A Rai, ¹⁰D Frei, ¹¹J Delgado Almandoz, ¹²M Kelly, ¹³A Arthur, ¹⁴B Baxter, ¹⁵J English, ¹⁶I Linfante, ¹⁷K Fargen, ⁷A Turk III, ²A Siddiqui, ³J Mocco. ¹University of South Florida, Tampa, FL; ²University of Buffalo, Buffalo, NY; ³Icahn School of Medicine at Mount Sinai, New York, NY; ⁴Stony Brook University, Stony Brook, NY; ⁵Baptist Medical Center, Jacksonville, FL; ⁶Fort Sanders Regional Medical Center, Knoxville, TN; ⁷Greenville Health System, Greenville, SC; ⁸Medical University of South Carolina, Charleston, SC; ⁹West Virginia University, Morgantown, WV; ¹⁰Swedish Medical Center, Englewood, CO; ¹¹Abbott Northwestern Hospital, Minneapolis, MN; ¹²University of Saskatchewan, Saskatoon, SK, CANADA; ¹³University of South Florida, Memphis, TN; ¹⁴Erlanger Medical Center, Chattanooga, TN; ¹⁵California Pacific Medical Center, San Francisco, CA; ¹⁶Baptist Cardiac and Vascular Institute, Miami, FL; ¹⁷Wake Forest Baptist Medical Center, Winston-Salem, NC

10.1136/neurintsurg-2020-SNIS.93

Background Imaging clot characteristics such as clot density and perviousness (the latter is defined as a difference in regional clot density values between computed tomography angiography (CTA) and non-contrast CT [NCCT]), can be used as an imaging marker characterizing red blood cell and fibrin composition of the clot serving. We aimed to examine whether clot density and perviousness were associated with angiographic outcomes of aspiration and stent retriever thrombectomy in the COMPASS Trial: a Direct Aspiration First Pass Technique trial.

Methods Clot density (Hounsfield units, HU) and perviousness were measured by two operators who were blind to all the final angiographic and clinical outcomes except for the knowledge of stroke laterality. NCCT and CTA images were co-registered to accurately localize clot on both imaging modalities. The values were then matched with angiographic and clinical outcome data of the first pass for each randomization arm. Univariate and multivariate analysis was carried out to assess the association of clot density and perviousness using SPSS version 25.

Results Of the original 270 patients included in the COMPASS trial, 165 were eligible for the post-hoc analysis (81 patients in the aspiration first and 84 in the stent retriever first groups). There was no difference between the groups in regards to gender distribution, age, laterality and side of large vessel occlusion, smoking status of patients, and comorbidities. There was also no difference between the aspiration and stent retriever first randomization groups in regards to baseline clot Hounsfield units (HU) on NCCT (49.9 ± 8.2 vs. 47.8 ± 8.7, P=0.11), and perviousness (26.84 ± 21.8 vs. 22.8 ± 19.9, P=0.20). For the aspiration first group, there was a difference in mean perviousness values among patients who achieved TICI 2c-3 vs. TICI 2b vs. TICI 0-2a (33.1 ± 26, 35.9 ± 25.1, and 19.0 ± 14.2, respectively; P=0.016).